FOLH1 and neoplasm: The inter-patient variability for absorbed doses to kidneys and tumor lesions after [177Lu]Lu-PSMA therapy was recently studied, showing high variability in absorbed doses to kidneys and tumors (coefficient of variation 31-59%) in the observed population 49.